Search clinical trials for: intensified chemotherapy (FOLFOXIRI/Bevacizumab)

Total 203 results

Fujian Cancer Hospital

Not yet recruiting

Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Advanced Colorectal Cancer
National Center for Tumor Diseases, Heidelberg
Pfizer; Roche Pharma AG

Terminated

Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy (APRIORI)

Colorectal Carcinoma

Germany
Hospital Universitari de Bellvitge
Instituto de Salud Carlos III

Terminated

Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases (CCRe-IV)

Colonic Cancer | Unresectable Metastasis Originating in Colonic Cancer

Spain
Institute of Oncology Ljubljana

Unknown

Induction Chemotherapy,Radiochemotherapy, Consolidation Chemotherapy in Preoperative Treatment of Rectal Cancer

Rectal Cancer

Slovenia
Seoul National University Hospital

Recruiting

Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12) (CLAUDIA)

Colon Cancer

Korea, Republic of
Sun Yat-sen University

Recruiting

Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Colon Cancer Stage II | Colon Cancer Stage III

China
Medical University of Vienna

Unknown

Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer (CARCINOSIS)

Colorectal Cancer | Peritoneal Metastasis

Austria
Gruppo Oncologico del Nord-Ovest

Completed

Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient (MACBETH)

Metastatic Colorectal Cancer

Italy
Hospices Civils de Lyon

Unknown

Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis (IPOXA)

Peritoneal Carcinosis

France
Spanish Cooperative Group for the Treatment of...
Roche Pharma AG

Completed

Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells (VISNU-1)

Metastatic Colorectal Cancer

Spain
Fudan University

Recruiting

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Colorectal Cancer | Liver Metastases

China
Karen-Lise Garm Spindler

Recruiting

IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer (IMPROVE-IT)

Colorectal Cancer | Adjuvant Chemotherapy | Circulating Tumor DNA | Progression Free Survival

Denmark
Institut Curie
UNICANCER

Completed

First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3)

Ewing Sarcoma Family of Tumors

France
Azienda Ospedaliero, Universitaria Pisana

Completed

Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer (TRUST)

Rectal Cancer

Italy
Hospices Civils de Lyon

Active, not recruiting

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer (BEVANEC)

Neuroendocrine Carcinomas

France
Fudan University

Recruiting

The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Dutch Colorectal Cancer Group

Recruiting

Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases (CAIRO5)

Colorectal Cancer | Liver Metastases

Netherlands, Belgium
Azienda Ospedaliero, Universitaria Pisana

Completed

First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Italy
Hunan Province Tumor Hospital

Completed

Immunochemotherapy or Chemotherapy in ALK-rearranged 5'-ALK NSCLC (CLASSIC5)

Non-small Cell Lung Cancer

China
Istituto Scientifico Romagnolo per lo Studio e...

Completed

Sequential Treatment Strategy for Metastatic Colorectal Cancer (ITACa)

Metastatic Colorectal Cancer

Italy
The First People's Hospital of Changzhou

Completed

Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer

Rectum Cancer
Federation Francophone de Cancerologie Digestive
Roche Pharma AG

Completed

1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer

Colorectal Cancer

France
Chinese PLA General Hospital

Unknown

A Pilot Study of Neoadjuvant Chemotherapy Combined With Bevacizumab for Locally Advanced Rectal Cancer

Rectal Cancer

China
Fudan University

Recruiting

IV Ascorbic Acid in Peritoneal Metastatic Colorectal Cancer

Colorectal Cancer | Vitamin C | GLUT3

China
Spanish Cooperative Group for the Treatment of...
Roche Pharma AG

Completed

Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (VISNU-2)

Colorectal Cancer Metastatic

Spain
Korea Cancer Center Hospital
Gachon University Gil Medical Center; The Catholic University of Korea; Gangnam... and other collaborators

Unknown

Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis

Rectal Cancer | Liver Metastasis | Lung Metastasis

Korea, Republic of
National Cancer Institute, Naples

Recruiting

Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer (ARBITRATION)

Metastatic Colorectal Cancer

Italy
ARCAGY/ GINECO GROUP

Active, not recruiting

PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer . (NEOPEMBROV)

Ovarian Cancer Stage IV

France
Fudan University

Unknown

Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases

Colorectal Cancer | Liver Metastases
Nanfang Hospital of Southern Medical University

Recruiting

The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM

Colorectal Neoplasms Malignant

China
Fudan University

Recruiting

Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer

Colorectal Cancer

China
Pfizer

Terminated

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

Ovarian Cancer

Korea, Republic of, United States, Singapore, Taiwan, Japan, Italy, Australia, Belgium, Ireland, Russian Federation
Yonsei University

Recruiting

Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases

Metastatic Colorectal Cancer

Korea, Republic of
Sun Yat-sen University

Unknown

FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type (FORBES)

Metastatic Colorectal Cancer

China
Genentech, Inc.

Completed

A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)

Brain Neoplasms | Non-Small Cell Lung Cancer
Li Liu

Unknown

VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

Non Small Cell Lung Cancer | Brain Metastasis

China
Azienda Ospedaliero, Universitaria Pisana

Completed

Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer (CIRCUS)

Metastatic Colorectal Cancer

Italy
Cho Ray Hospital
University of Medicine and Pharmacy at Ho Chi Minh City

Recruiting

Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer

Synchronous Neoplasm | Liver Metastasis Colon Cancer

Vietnam
Intergroupe Francophone de Cancerologie Thoracique

Completed

Bevacizumab in Extensive Small Cell Lung Cancer (CPC)

Small Cell Lung Cancer

France
Fudan University

Recruiting

VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

Colorectal Cancer

China
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Non-Squamous Non-Small Cell Lung Cancer

Australia, France, Germany, Spain, China, Hong Kong, Canada, Sweden, Colombia, Taiwan, United Kingdom, Russian Federation, Finland, Austria, Estonia, Hungary, Netherlands, Latvia, Italy, Mexico, Slovenia, Turkey, Bosnia and Herzegovina and more
Yonsei University

Completed

Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets

Colorectal Cancer | Liver Metastasis

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

Breast Cancer

Israel, Spain, France, Greece, Germany, Austria, Italy, Hungary, Croatia, Argentina, Brazil, Slovakia, Switzerland
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

Rectal Cancer | Colon Cancer | Hepatic Metastases

United States
Liaoning Tumor Hospital & Institute

Unknown

Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer

Colorectal Cancer | Liver Metastases

China
Memorial Sloan Kettering Cancer Center

Completed

Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC

Carcinoma, Non-Small-Cell Lung

United States
Koen Rovers
Hoffmann-La Roche; Comprehensive Cancer Centre The Netherlands; Dutch Cancer...

Recruiting

Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (CAIRO6)

Colorectal Cancer | Peritoneal Neoplasms | Colorectal Neoplasm | Peritoneal Carcinomatosis | Colorectal Carcinoma | Peritoneal Cancer | Peritoneal Metastases | Colorectal Adenocarcinoma | Colorectal Neoplasms Malignant | Peritoneal Neoplasm Malignant Secondary Carcinomatosis | Peritoneal Neoplasm Malignant...

Netherlands, Belgium
Hoffmann-La Roche

Completed

Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin) (CONCERT)

Metastatic Colorectal Cancer

France
Fujian Cancer Hospital

Not yet recruiting

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Lung Adenocarcinoma | PD-1 Inhibitor | Stage IV Non-small Cell Lung Cancer | VEGF
Memorial Sloan Kettering Cancer Center

Completed

Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC

Carcinoma, Non-Small-Cell Lung

United States

3

Subscribe